The Relative Strength (RS) Rating for Xencor jumped into a new percentile Wednesday, with an increase from 79 to 83.
This exclusive rating from Investor's Business Daily tracks share price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the trailing 52 weeks stacks up against all the other stocks in our database.
History shows that the market's biggest winners tend to have an RS Rating north of 80 as they begin their biggest climbs.
Hone Your Stock-Picking Skills By Focusing On These Factors
Xencor is trying to complete a consolidation with a 25.41 entry. See if the stock can break out in heavy trading.
Xencor posted 0% EPS growth in its most recent report, while sales growth came in at -82%.
The company earns the No. 186 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Exelixis and Corcept Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
